Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
ENYO Pharma logo — Developing therapeutics for diseases with impaired kidney fu...

ENYO Pharma

Developing therapeutics for diseases with impaired kidney function

Founded 2014 France France 35 employees Series C Total: $103.50M Biopharma, Biotechnology

General Information

Company Name ENYO Pharma
Founded Year 2014
Location France France +1
Founders / Decision Makers
Team member
Employees 35
Industries Biopharma, Biotechnology
Funding Stage Series C
Social

Get notified when ENYO Pharma moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About ENYO Pharma

ENYO Pharma is a biopharmaceutical company that focuses on developing therapeutics for diseases with impaired kidney function. The company's lead compound, Vonafexor, is currently undergoing Phase 2 trials for Chronic Kidney Diseases (CKD), rare kidney diseases such as Alport syndrome, and liver diseases, including Non-Alcoholic SteatoHepatitis (NASH). Additionally, Vonafexor is also targeted towards liver-related infectious diseases like chronic Hepatitis B and Hepatitis D. Founded in 2014 and headquartered in France, ENYO Pharma recently received a significant €39.00M Series C investment on 03 January 2024. The investment was made by notable firms such as OrbiMed, Andera Partner, Bpifrance Large Venture, Bpifrance InnoBio, and Morningside Venture Investments. The company's innovative approach to addressing a range of kidney and liver diseases through its therapeutic compounds positions it as an emerging player in the biopharmaceutical industry.

Taxonomy: Biopharmaceuticals, Therapeutics, Chronic Kidney Diseases, Rare Kidney Diseases, Liver Diseases, Infectious Diseases, Vonafexor, Intracellular Therapeutic Targets, Anti-virals, Drug Development, Phase 2 Trials, Research and Development, Inserm Patents, Viral Treatments, Global Leader

Services & Products

Developing therapeutics for diseases with impaired kidney function

Target Customers

Patients with impaired kidney function pharmaceutical companies research institutions

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series C •••••• 5
Investor Investor
•••• •••• 		03 Jan 2024
Series B •••••• 5
Investor Investor Investor
•••• •••• 		04 Jun 2018
Grant •••••• 1 •••• •••• 06 Dec 2016
Series A •••••• 1
Investor
03 Jan 2016

ENYO Pharma Alternatives & Competitors

ENYO Pharma vs
Aligos Therapeutics
Aligos Therapeutics United States

Improving patient outcomes through best-in-class therapies for liver and viral diseases

Unknown
97 employees
Biotechnology
Compare ENYO Pharma vs Aligos Therapeutics
ENYO Pharma vs
Tricida, Inc.
Tricida, Inc. United States

Tricida is a pharmaceutical company working to turn the tide on metabolic acidosis and progression o...

Post Ipo Debt
16 employees
Health Care, Pharmaceutical
Compare ENYO Pharma vs Tricida, Inc.
ENYO Pharma vs
NEPHROLOGY ASSOCIATES OF THE GULF COAST, PA
NEPHROLOGY ASSOCIATES OF THE GULF COAST, PA United States

Trusted expertise in kidney care and treatment, from diagnosis to advanced procedures.

22 employees
Digital Health, Health Care
Compare ENYO Pharma vs NEPHROLOGY ASSOCIATES OF THE GULF COAST, PA
Also compare with: ENYO Pharma vs Intercept Pharmaceuticals Intercept Pharmaceuticals

FAQ About ENYO Pharma

Developing therapeutics for diseases with impaired kidney function
ENYO Pharma was founded in 2014.
ENYO Pharma is headquartered in France.
ENYO Pharma operates in the following industries: Biopharma, Biotechnology.
ENYO Pharma has approximately 35 employees.
ENYO Pharma has completed 4 funding rounds, raising a total of $103.50M. The latest funding stage is Series C.
ENYO Pharma offers: Developing therapeutics for diseases with impaired kidney function.
Top alternatives and competitors to ENYO Pharma include Aligos Therapeutics, Tricida, Inc., NEPHROLOGY ASSOCIATES OF THE GULF COAST, PA, Clinical Renal Associates, Rejuvenate Bio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ENYO Pharma and Aligos Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors ENYO Pharma and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes